Biotech and Pharma News Editor - London, United Kingdom - Financial Times

Financial Times

Verified Company

London, United Kingdom

2 weeks ago

Posted by:

Tom O´Connor

beBee Recruiter

Description

TITLE:
Biotech and Pharma News Editor (UK-based)

SALARY:
£55-85,000

LOCATION:
United Kingdom

Experience: 5+ years

DESCRIPTION:

Endpoints News is seeking a UK-based editor to work closely with our US team on our daily news and longer-term coverage planning.

We're an ambitious specialty publication with more than 160,000 subscribers, and we publish three newsletters a day covering the waterfront in the biopharma industry.

In the role, you'll help drive our industry-leading coverage of the most important breaking news, as well as work on scoops and smart analysis.

We start early in the US morning, and a typical day will involve coordinating with our Asia team to spot breaking news and then working with our US reporters as they log on.

We cover everything that matters in biopharma:
fast news hits, complex medical studies, major M&A deals, VC fundraising and corporate layoffs and reorganizations.

You'll help journalists find the right angle for the story, talk through reporting and writing, and work on their copy.

As the day goes on and the pace of breaking news abates, you'll hand off our coverage to the rest of the US team and have opportunities to get involved in longer-lead projects.

WHO WE ARE:

Endpoints News, a leading B2B media company, was founded in 2016 with a clear mission: deliver the best news product in biopharma and become an essential read for industry leaders across the globe.

Seven years later, we now have 164,000 subscribers and a team of journalists and staff in the US, Europe, and Asia.

We're read daily by thousands of innovative biotechs and every top 50 pharmaceutical company in the world.

Our editorial ambitions continue to grow as we complement our breaking news and daily analysis with original scoops, in-depth features and live journalism at the industry's most important gatherings.

We are now a part of the Financial Times family.

LI-KF1